OXB
Total Voting Rights
Oxford, UK - 01 November 2024: Oxford Biomedica Plc ( "OXB" or the "Company"; LSE: OXB), a
quality and innovation-led cell and gene therapy CDMO, today
announces that in accordance
with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R,
the Company's issued share capital as at the close of business on
31 October 2024 consisted of 105,923,083 ordinary shares of 50 pence each ("Ordinary Shares"). There
are no Ordinary Shares held in treasury.
Accordingly, the total number of
voting rights in OXB at the date of this notice
is 105,923,083.
The above figure 105,923,083 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, OXB under the FCA's Disclosure Guidance and
Transparency Rules.
-Ends-
Enquiries:
|
Oxford Biomedica plc:
Natalie Walter, Company
Secretary
|
Tel: +44 (0)1865 783 000
|
About OXB
OXB (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology
companies, providing viral vector development and
manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class
capabilities span from early stage development to
commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods
and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer
and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on LinkedIn
and YouTube.